- Home
- HQI vs GOSS Comparison
HQI vs GOSS Comparison
Compare HQI & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQI
- GOSS
- Stock Information
- Founded
- HQI 2002
- GOSS 2015
- Country
- HQI United States
- GOSS United States
- Employees
- HQI N/A
- GOSS N/A
- Industry
- HQI Professional Services
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- HQI Consumer Discretionary
- GOSS Health Care
- Exchange
- HQI Nasdaq
- GOSS Nasdaq
- Market Cap
- HQI 196.4M
- GOSS 212.9M
- IPO Year
- HQI N/A
- GOSS 2019
- Fundamental
- Price
- HQI $14.43
- GOSS $0.74
- Analyst Decision
- HQI Strong Buy
- GOSS Strong Buy
- Analyst Count
- HQI 2
- GOSS 5
- Target Price
- HQI $18.00
- GOSS $9.20
- AVG Volume (30 Days)
- HQI 11.7K
- GOSS 881.6K
- Earning Date
- HQI 11-07-2024
- GOSS 11-07-2024
- Dividend Yield
- HQI 1.68%
- GOSS N/A
- EPS Growth
- HQI N/A
- GOSS N/A
- EPS
- HQI 0.10
- GOSS N/A
- Revenue
- HQI $36,279,000.00
- GOSS $105,322,000.00
- Revenue This Year
- HQI N/A
- GOSS N/A
- Revenue Next Year
- HQI $8.01
- GOSS N/A
- P/E Ratio
- HQI $101.70
- GOSS N/A
- Revenue Growth
- HQI 0.28
- GOSS N/A
- 52 Week Low
- HQI $11.39
- GOSS $0.50
- 52 Week High
- HQI $17.31
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- HQI 55.60
- GOSS 22.63
- Support Level
- HQI $14.25
- GOSS $0.78
- Resistance Level
- HQI $14.76
- GOSS $0.92
- Average True Range (ATR)
- HQI 0.57
- GOSS 0.05
- MACD
- HQI 0.08
- GOSS -0.01
- Stochastic Oscillator
- HQI 84.04
- GOSS 0.00
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The primary source of revenue for the company is royalty fees based on the operation of its franchised offices.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.